Skip to main content

Table 1 Parameters for calculation of event rates, costs and QALYs with QIV versus TIV

From: Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong

Parameter

Values

References

Clinical inputs

  

  Influenza vaccine coverage (≥65 years)

39.1%

15

  TIV vaccine effectiveness against influenza B (2001–2010)

0.45-0.75

7-14

  Reduction in TIV influenza B vaccine effectiveness against TIV-unmatched influenza B lineage

30%

6

  Influenza B hospitalization rate (2001–2010) by age group (per 100,000):

 

1

  65-79 years

1-40.8

 

  ≥ 80 years

0-222.1

 

  Hong Kong population (2001−2010) by age group:

 

24

  65-79 years

600,986-665,642

 

  ≥ 80 years

146,066-257,966

 

  Influenza B lineage in circulation (2001−2010)

 

1

  Yamagata

5.3%-96.3%

 

  Victoria

3.7-94.7%

 

  Case-fatality ratio

0.05%

5

  Percent of inpatient cases with ICU admission:

2.4%

4

  Mortality rate of influenza B in ≥65 years inpatient cases

5.9%

1

Utility

  

  Utility score for >65 years

0.84

25

  Utility loss

 

16-22

  Outpatient care

0.40

 

  Hospitalization without ICU care

0.50

 

  Hospitalization with ICU care

0.62

 

  Life expectancy in Hong Kong (years)

83

24

Cost (USD)*

  

  Cost of outpatient clinic (per visit)

49

26

  Number of clinic visit for patients without hospitalization

1

Assumption

  Cost of hospitalization without ICU care (per day)

600

26

  Cost of hospitalization with ICU care (per day)

2,949

26

  Length of illness (days)

  

  Outpatient care

7

23

  Hospitalization (length of stay)

10.8

4

  Caregiver salary per day

47

24

  Labor force rate

68%

24

  Unemployment rate

3.7%

24

  1. *1 USD =7.8 HKD.